Stigma, colorectal cancer knowledge and self-efficacy among colorectal cancer survivors: A cross-sectional study based on random forest analysis.

Purpose: To assess the stigma levels among colorectal cancer (CRC) survivors, identify determinants, examine correlations with CRC knowledge and self-efficacy, and quantify the relative influence of various contributing factors.

Methods: In total, 301 CRC survivors were enrolled from a tertiary oncology center in southern China. The participants completed the Social Impact Scale (SIS), Bowel Cancer Awareness Measure (Bowel CAM), General Self-Efficacy Scale (GSES), and a demographic and disease-related questionnaire.

The role of lncRNAs in AKI and CKD: Molecular mechanisms, biomarkers, and potential therapeutic targets.

Exosomes, a type of extracellular vesicle, are commonly found in different body fluids and are rich in nucleic acids (circRNA, lncRNAs, miRNAs, mRNAs, tRNAs, .), proteins, and lipids. They are involved in intercellular communication.

AMPK agonist AICAR ameliorates maternal hepatic lipid metabolism disorder, inflammation, and fibrosis caused by PM exposure during pregnancy.

Liver is an important target organ of ambient fine particulate matter (PM). Numerous studies have shown that PM exposure can cause liver lipid metabolism disorders and other liver damage in mammals. However, the impact of PM on liver health during pregnancy, a sensitive life stage, remains understudied, and the underlying mechanisms are also unknown.

Status of Cardiac Magnetic Resonance in Clinical Application and Scientific Research: A National Survey in China.

Background: Cardiovascular magnetic resonance (CMR) is rapidly expanding in China, yet comprehensive national data on its clinical application and research status are limited. This study aims to evaluate the current landscape of CMR across the country.

Methods: An electronic survey was conducted targeting two groups: physicians trained at the Fuwai Fellowship Program and members of the Chinese Society of Radiology.

High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy.

Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitor (ICI) therapy, particularly with PD-1 inhibitors like nivolumab, has become a critical treatment option for advanced NSCLC. ICI therapy has revolutionized treatment, but prior chemotherapy may diminish ICI treatment efficacy.